These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12438542)

  • 21. Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.
    Piot O; Betschart J; Grall I; Ravard S; Garret C; Blanchard JC
    Br J Pharmacol; 1995 Nov; 116(5):2496-502. PubMed ID: 8581290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
    Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
    J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.
    Cellier E; Barbot L; Iyengar S; Couture R
    Br J Pharmacol; 1999 Jun; 127(3):717-28. PubMed ID: 10401563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Action of substance P (neurokinin-1) receptor activation on rat neostriatal projection neurons.
    Galarraga E; Hernández-López S; Tapia D; Reyes A; Bargas J
    Synapse; 1999 Jul; 33(1):26-35. PubMed ID: 10380848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Permissive role of neurokinin NK(3) receptors in NK(1) receptor-mediated activation of the locus coeruleus revealed by SR 142801.
    Bert L; Rodier D; Bougault I; Allouard N; Le-Fur G; Soubrié P; Steinberg R
    Synapse; 2002 Jan; 43(1):62-9. PubMed ID: 11746734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [SAR9,MET(O2)11]substance P.
    Yip J; Chahl LA
    Neuroscience; 1999; 94(2):663-73. PubMed ID: 10579226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurokinin-1 receptors modulate the excitability of expiratory neurons in the ventral respiratory group.
    Fong AY; Potts JT
    J Neurophysiol; 2008 Feb; 99(2):900-14. PubMed ID: 18057111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
    Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
    J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substance P excites globus pallidus neurons in vivo.
    Cui QL; Yung WH; Xue Y; Chen L
    Eur J Neurosci; 2007 Oct; 26(7):1853-61. PubMed ID: 17868370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
    Tsuchida H; Takahashi S; Nosaka E; Kuraya T; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 Oct; 596(1-3):153-9. PubMed ID: 18706408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.
    Iyengar S; Hipskind PA; Gehlert DR; Schober D; Lobb KL; Nixon JA; Helton DR; Kallman MJ; Boucher S; Couture R; Li DL; Simmons RM
    J Pharmacol Exp Ther; 1997 Feb; 280(2):774-85. PubMed ID: 9023291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
    Juszczak M
    Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
    Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
    J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism.
    Salthun-Lassalle B; Traver S; Hirsch EC; Michel PP
    Mol Pharmacol; 2005 Nov; 68(5):1214-24. PubMed ID: 16077032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of MDL 105,212, a nonpeptide NK-1/NK-2 receptor antagonist in an allergic guinea pig model.
    Kudlacz EM; Knippenberg RW; Logan DE; Burkholder TP
    J Pharmacol Exp Ther; 1996 Nov; 279(2):732-9. PubMed ID: 8930178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
    Brocco M; Dekeyne A; Mannoury la Cour C; Touzard M; Girardon S; Veiga S; de Nanteuil G; deJong TR; Olivier B; Millan MJ
    Eur Neuropsychopharmacol; 2008 Oct; 18(10):729-50. PubMed ID: 18657401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurokinin-1 receptors in the rat nucleus tractus solitarius: pre- and postsynaptic modulation of glutamate and GABA release.
    Bailey CP; Maubach KA; Jones RS
    Neuroscience; 2004; 127(2):467-79. PubMed ID: 15262336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical localization of substance P NK1 receptor in guinea pig distal colon.
    Harrington AM; Hutson JM; Southwell BR
    Neurogastroenterol Motil; 2005 Oct; 17(5):727-37. PubMed ID: 16185312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.